

Cancer

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03330990 GO40785
RXDX-101-14

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03330990 GO40785 RXDX-101-14
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
